Vera Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VERA research report →
Companyveratx.com
Vera Therapeutics, Inc. , a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy.
- CEO
- Gary Barrera
- IPO
- 2021
- Employees
- 152
- HQ
- Brisbane, CA, US
Price Chart
Valuation
- Market Cap
- $2.49B
- P/E
- -6.71
- P/S
- 0.00
- P/B
- 4.95
- EV/EBITDA
- -6.74
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -74.86%
- ROIC
- -66.50%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-299,615,000 · -96.92%
- EPS
- $-4.66 · -69.45%
- Op Income
- $-315,473,000
- FCF YoY
- -78.20%
Performance & Tape
- 52W High
- $56.05
- 52W Low
- $18.76
- 50D MA
- $39.20
- 200D MA
- $35.89
- Beta
- 0.95
- Avg Volume
- 1.21M
Get TickerSpark's AI analysis on VERA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 12, 26 | Fordyce Marshall | sell | 14,219 |
| May 12, 26 | Fordyce Marshall | sell | 4,281 |
| Apr 14, 26 | Fordyce Marshall | sell | 14,130 |
| Apr 14, 26 | Fordyce Marshall | sell | 7,921 |
| Apr 14, 26 | Fordyce Marshall | sell | 900 |
| Mar 23, 26 | Wright-Mitchell Jane | other | 56,850 |
| Mar 23, 26 | Wright-Mitchell Jane | other | 42,403 |
| Mar 23, 26 | Wright-Mitchell Jane | other | 0 |
| Mar 13, 26 | Young Joseph R | other | 10,000 |
| Mar 13, 26 | Young Joseph R | other | 10,000 |
Our VERA Coverage
We haven't published any research on VERA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate VERA Report →